+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors Results from a phase I study



Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors Results from a phase I study



European Journal of Cancer 37(Suppl. 6): S73




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 034812889

Download citation: RISBibTeXText

DOI: 10.1016/s0959-8049(01)80749-8


Related references

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Annals of Oncology 16(8): 1391-1397, 2005

ZD6474 Design, synthesis and structure activity relationship of a novel, orally active VEGF receptor tyrosine kinase inhibitor. Proceedings of the American Association for Cancer Research Annual Meeting 42: 587, 2001

Antitumor effects of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor that is also active against EGF receptor tyrosine kinase. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1080-1081, 2002

A novel orally active dual inhibitor of VEGF receptor 1 and 2 tyrosine kinase KRN633 Anti-angiogenic and anti-tumor activity against human solid tumors. Proceedings of the American Association for Cancer Research Annual Meeting 43: 175, 2002

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Molecular Cancer Therapeutics 8(11): 3151-3161, 2009

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of Clinical Oncology 20(9): 2240-2250, 2002

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology 26(15_Suppl): 2530-2530, 2016

Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 (P) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 26(15_Suppl): 2529-2529, 2016

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer 103: 17-23, 2018

HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. Journal of Clinical Oncology 24(18_Suppl): 3018-3018, 2016

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Annals of Oncology 22(11): 2508-2515, 2011

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Science 95(12): 984-989, 2004

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clinical Cancer Research 15(7): 2552-2558, 2009

ZD4190 An orally active inhibitor of VEGF receptor tyrosine kinase activity. British Journal of Cancer 80(Suppl. 2): 92, 1999

ZD6474 An inhibitor of VEGF receptor tyrosine kinase activity. Clinical & Experimental Metastasis 17(9): 776, 1999( ), 2000